{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:41:43Z","timestamp":1785937303658,"version":"3.56.0"},"reference-count":46,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T00:00:00Z","timestamp":1696723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Stroke is a leading cause of mortality and morbidity worldwide. Treatment of this pathology is still under development and its risk factors remain to be determined. Therefore, we aim to determine the role of interleukin-1 beta in atherosclerotic lesions of the internal carotid artery as a risk factor for stroke and the role of this biomarker in stroke prognosis. Materials and Methods: This study enrolled 56 patients diagnosed with ischemic stroke in the anterior vascular territory (AVT) and posterior vascular territory (PVT). All the patients had venous blood collected at admission and 7 days after the onset of the cerebral ischemia in order to determine the plasma concentration of interleukin-1 beta. At the same time, an extracranial carotid ultrasound was performed. Results: The interleukin-1 beta collected at admission was positively correlated with the NIHSS at admission (Pearson index 0.424), and both measurements were correlated with carotid stenosis (Spearmen correlation index of 0.529 and 0.653, respectively). Conclusions: Interleukin-1 beta could be a reliable biomarker for stroke prognosis and the development of atherosclerotic lesions of the internal carotid.<\/jats:p>","DOI":"10.3390\/medicina59101790","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T04:56:43Z","timestamp":1696827403000},"page":"1790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["IL-1 Beta\u2014A Biomarker for Ischemic Stroke Prognosis and Atherosclerotic Lesions of the Internal Carotid Artery"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4392-8522","authenticated-orcid":false,"given":"Maria-Gabriela","family":"Catan\u0103","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, Izvorului Street, 550169 Sibiu, Romania"},{"name":"Neurology Department, Emergency County Clinical Hospital Sibiu, Corneliu Coposu bvd, 550245 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3559-9547","authenticated-orcid":false,"given":"Ioan-Adrian","family":"Popen\u021biu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, Izvorului Street, 550169 Sibiu, Romania"},{"name":"Department of General Surgery, \u201cAlexandru Augustin\u201d Military Emergency Hospital, Victoriei bvd, 550024 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u0103d\u0103lina","family":"V\u0103leanu","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d Cluj-Napoca, 7 Horea Street, 400174 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Roman-Filip","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, Izvorului Street, 550169 Sibiu, Romania"},{"name":"Neurology Department, Emergency County Clinical Hospital Sibiu, Corneliu Coposu bvd, 550245 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romeo-Gabriel","family":"Mih\u0103il\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, Izvorului Street, 550169 Sibiu, Romania"},{"name":"Hematology Department, Emergency County Clinical Hospital Sibiu, Sibiu Corneliu Coposu bvd, 550245 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12974-019-1516-2","article-title":"Neuroinflammation: Friend and foe for ischemic stroke","volume":"16","author":"Jayaraj","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2174\/0929867321666131228205146","article-title":"Innate inflammatory responses in stroke: Mechanisms and potential therapeutic targets","volume":"21","author":"Kim","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000332205","article-title":"Interleukin-1 and stroke: Biomarker, harbinger of damage, and therapeutic target","volume":"32","author":"Denes","year":"2011","journal-title":"Cerebrovasc. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jstrokecerebrovasdis.2008.11.009","article-title":"Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke","volume":"18","author":"Banwell","year":"2009","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2008.10.008","article-title":"Cell-specific and concentration-dependent actions of interleukin-1 in acute brain inflammation","volume":"45","author":"Pinteaux","year":"2009","journal-title":"Cytokine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/clinchem\/hvaa275","article-title":"Inflammation in atherosclerosis\u2014No longer a theory","volume":"67","author":"Libby","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nguyen, M., Fernando, S., Schwarz, N., Tan, J., Bursill, C., and Psaltis, P. (2019). Inflammation as a therapeutic target in atherosclerosis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8081109"},{"key":"ref_8","first-page":"927","article-title":"Atherosclerosis: Process, indicators, risk factors and new hopes","volume":"5","author":"Setorki","year":"2014","journal-title":"Int. J. Prev. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gregersen, I., and Halvorsen, B. (2018). Inflammatory Mechanisms in Atherosclerosis. Atherosclerosis-Yesterday, Today and Tomorrow, InTech.","DOI":"10.5772\/intechopen.72222"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chistiakov, D.A., Kashirskikh, D.A., Khotina, V.A., Grechko, A.V., and Orekhov, A.N. (2019). Immune-inflammatory responses in atherosclerosis: The role of myeloid cells. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111798"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00702-017-1732-9","article-title":"The IL-1\u03b2 phenomena in neuroinflammatory diseases","volume":"125","author":"Mendiola","year":"2018","journal-title":"J. Neural Transm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e16269","DOI":"10.15252\/emmm.202216269","article-title":"Systemic inflammation after stroke: Implications for post-stroke comorbidities","volume":"14","author":"Simats","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/cei.13551","article-title":"A hyperacute immune map of ischaemic stroke patients reveals alterations to circulating innate and adaptive cells","volume":"203","author":"Krishnan","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jurcau, A., and Simion, A. (2021). Neuroinflammation in cerebral ischemia and ischemia\/reperfusion injuries: From pathophysiology to therapeutic strategies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010014"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1523\/JNEUROSCI.21-15-05528.2001","article-title":"Role of IL-1\u03b1 and IL-1\u03b2 in ischemic brain damage","volume":"21","author":"Boutin","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cyto.2012.02.016","article-title":"Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression","volume":"58","author":"Smith","year":"2012","journal-title":"Cytokine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/CIA.S233909","article-title":"The role of selected proinflammatory cytokines in pathogenesis of ischemic stroke","volume":"15","author":"Pawluk","year":"2020","journal-title":"Clin. Interv. Aging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/STROKEAHA.118.020750","article-title":"SCIL-STROKE (subcutaneous interleukin-1 receptor antagonist in ischemic stroke) a randomized controlled phase 2 trial","volume":"49","author":"Smith","year":"2018","journal-title":"Stroke"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Emsley, H.C., Smith, C.J., Gavin, C.M., Georgiou, R.F., Vail, A., Barberan, E.M., Illingworth, K., Scarth, S., Wickramasinghe, V., and Hoadley, M.E. (2007). Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol., 7.","DOI":"10.1186\/1471-2377-7-5"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Stone, M.J., Hayward, J.A., Huang, C., Huma, Z.E., and Sanchez, J. (2017). Mechanisms of regulation of the chemokine-receptor network. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020342"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"701976","DOI":"10.1155\/2012\/701976","article-title":"Interleukin-1\u03b2 accelerates the onset of stroke in stroke-prone spontaneously hypertensive rats","volume":"2012","author":"Chiba","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-021-02177-0","article-title":"Stroke-induced immunosuppression: Implications for the prevention and prediction of post-stroke infections","volume":"18","author":"Faura","year":"2021","journal-title":"J. Neuroinflammat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.4049\/jimmunol.1102289","article-title":"Brain-derived antigens in lymphoid tissue of patients with acute stroke","volume":"188","author":"Planas","year":"2012","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"589654","DOI":"10.3389\/fimmu.2020.589654","article-title":"Targeting IL-1\u03b2 in the Treatment of Atherosclerosis","volume":"11","author":"Mai","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41591-018-0124-5","article-title":"Interleukin-1\u03b2 has atheroprotective effects in advanced atherosclerotic lesions of mice","volume":"24","author":"Gomez","year":"2018","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.ATV.16.8.1000","article-title":"Interleukin-1\u03b2 in coronary arteries of patients with ischemic heart disease","volume":"16","author":"Galea","year":"1996","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.immuni.2021.02.004","article-title":"Post-injury immunosuppression and secondary infections are caused by an AIM2 inflammasome-driven signaling cascade","volume":"54","author":"Roth","year":"2021","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/eurheartj\/ehac094","article-title":"Targeting the CCL2\u2013CCR2 axis for atheroprotection","volume":"43","author":"Georgakis","year":"2022","journal-title":"Eur. Hear. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.18632\/oncotarget.12201","article-title":"Changes in the cellular immune system and circulating inflammatory markers of stroke patients","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1172\/JCI118476","article-title":"Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor","volume":"97","author":"Shimokawa","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2353\/ajpath.2006.051054","article-title":"Interleukin-1\u03b2 and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice","volume":"168","author":"Chamberlain","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/01.CIR.97.3.242","article-title":"Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E\u2013deficient mice","volume":"97","author":"Elhage","year":"1998","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1073\/pnas.092324399","article-title":"Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size","volume":"99","author":"Devlin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1\u03b2 decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mce.2009.07.029","article-title":"Association between interleukin-1 beta polymorphism (+3953) and obesity","volume":"314","author":"Bittencourt","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_38","unstructured":"Weir, C.B., and Jan, A. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_42","first-page":"174","article-title":"Closing the loop on inflammation and atherothrombosis: Why perform the CIRT and CANTOS trials?","volume":"124","author":"Ridker","year":"2013","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/2396987320972566","article-title":"Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE)\u2013study protocol for a randomised controlled trial","volume":"6","author":"Kelly","year":"2021","journal-title":"Eur. Stroke J."},{"key":"ref_46","unstructured":"(2023, September 15). National Heart, Lung, and Blood Institute (NHLBI). Rilonacept to Improve Artery Function in Patients with Atherosclerosis [ClinicalTrials.gov identifier NCT00417417]. US National Institutes of Health, Clinical Trials.gov, Available online: www.clinicaltrials.gov."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:02:58Z","timestamp":1760130178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,8]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["medicina59101790"],"URL":"https:\/\/doi.org\/10.3390\/medicina59101790","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,8]]}}}